

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2018 年)

1. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.

Konishi S, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Fujita N, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Masumori N, Kitamura H, Ohyama C. *Med Oncol*. 2018 Nov 24;36(1):6. doi: 10.1007/s12032-018-1231-3. PMID: 30474747

2. Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.

Shindo T, Kobayashi K, Tanaka T, Masumori N. *Support Care Cancer*. 2018 Oct 29. doi: 10.1007/s00520-018-4521-6. [Epub ahead of print] PMID: 30374764

3. Re: Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.

Tanaka T, Masumori N. *Int J Urol*. 2018 Dec;25(12):1017-1018. doi: 10.1111/iju.13810. Epub 2018 Sep 30. No abstract available. PMID: 30269361

4. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T. *Clin Genitourin Cancer*. 2018 Dec;16(6):e1201-e1214. doi: 10.1016/j.clgc.2018.07.028. Epub 2018 Aug 11.

PMID: 30224330

5. Modified Nephrometry Score With Body Mass Index More Accurately Predicts Ischemic Time in Transabdominal Laparoscopic Partial Nephrectomy for Small Renal Masses.

Masumori N, Ichihara K, Maehana T.

Urology. 2018 Sep 13. pii: S0090-4295(18)30948-8. doi: 10.1016/j.urology.2018.09.002.

[Epub ahead of print]

PMID: 30219558

6. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.

Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, Brotherton B, Wilson T, Muganurmath C, McLaughlin M, Manyak M.

Int J Urol. 2018 Nov;25(11):944-951. doi: 10.1111/iju.13785. Epub 2018 Sep 9.

PMID: 30198102

7. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.

Okabe K, Shindo T, Maehana T, Nishiyama N, Hashimoto K, Itoh N, Takahashi A, Taguchi K, Tachiki H, Tanaka T, Masumori N.

Jpn J Clin Oncol. 2018 Oct 1;48(10):934-941. doi: 10.1093/jjco/hyy122.

PMID: 30169681

8. Silodosin as second-line α -blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.

Ichihara K, Masumori N, Iwasawa A, Taguchi K, Yamaguchi Y, Nishimura M, Sasamura H, Suzuki N, Haga K, Miyao N, Hirose T.

Int J Urol. 2018 Oct;25(10):849-854. doi: 10.1111/iju.13757. Epub 2018 Aug 1.

PMID: 30066966

9. [Necrotizing Fasciitis and Frostbite of the Male External Genitalia : A Case Repor].

Yorozuya W, Kobayashi K, Nofuji S, Matsuki M, Hashimoto K, Kato S, Masumori N.

Hinyokika Kiyo. 2018 Jun;64(6):283-285. doi: 10.14989/ActaUrolJap_64_6_283. Japanese.

PMID: 30064168

10. Contribution of Novel Amino Acid Alterations in PmrA or PmrB to Colistin Resistance in mcr-Negative Escherichia coli Clinical Isolates, Including Major Multidrug-Resistant Lineages O25b:H4-ST131-H30Rx and Non-x.

Sato T, Shiraishi T, Hiyama Y, Honda H, Shinagawa M, Usui M, Kuronuma K, Masumori N, Takahashi S, Tamura Y, Yokota SI.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00864-18. doi: 10.1128/AAC.00864-18. Print 2018 Sep.

PMID: 29914952

11. Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer.

Shindo T, Niinuma T, Nishiyama N, Shinkai N, Kitajima H, Kai M, Maruyama R, Tokino T, Masumori N, Suzuki H.

Oncotarget. 2018 May 11;9(36):24457–24469. doi: 10.18632/oncotarget.25326. eCollection 2018 May 11.

PMID: 29849953 Free PMC Article

12. Bacillus Calmette–Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study.

Yorozuya W, Nishiyama N, Shindo T, Kyoda Y, Itoh N, Sugita S, Hasegawa T, Masumori N. Jpn J Clin Oncol. 2018 Jul 1;48(7):661–666. doi: 10.1093/jjco/hyy066.

PMID: 29733363

13. Evaluation of Usefulness of Propiverine Hydrochloride in Poor Responders to Previous Anticholinergics.

Masumori N, Funato Y, Yamaguchi Y, Itoh K.

Low Urin Tract Symptoms. 2018 May;10(2):116–121. doi: 10.1111/luts.12145. Epub 2016 Nov 5.

PMID: 29664239

14. Management of fungus balls as a result of Candida albicans.

Hiyama Y, Takahashi S, Masumori N.

Int J Urol. 2018 Jun;25(6):635–636. doi: 10.1111/iju.13576. Epub 2018 Apr 12. No abstract available.

PMID: 29651803

15. Laparoscopic Surgery for Seminal Vesicle Cysts and Ureterocele with Urination Disorder: A Case Report of Zinner Syndrome.

Maehana T, Fukuta F, Kobayashi K, Hirobe M, Tanaka T, Masumori N.

J Endourol Case Rep. 2018 Mar 1;4(1):35–38. doi: 10.1089/cren.2018.0008. eCollection 2018.

PMID: 29588919 Free PMC Article

16. Upper tract urothelial carcinoma following intravesical bacillus Calmette–Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.

Nishiyama N, Hotta H, Takahashi A, Yanase M, Itoh N, Tachiki H, Miyao N, Matsukawa M, Kunishima Y, Taguchi K, Kitamura H, Masumori N.

Urol Oncol. 2018 Jun;36(6):306.e9–306.e15. doi: 10.1016/j.urolonc.2018.02.009. Epub 2018 Mar 15.

PMID: 29550096

17. Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan.

Hirobe M, Tanaka T, Shindo T, Ichihara K, Hotta H, Takahashi A, Kato R, Yanase M, Matsukawa M, Itoh N, Kunishima Y, Taguchi K, Horita H, Masumori N.

Int J Clin Oncol. 2018 Aug;23(4):734–741. doi: 10.1007/s10147-018-1245-z. Epub 2018 Feb 13.

PMID: 29442282

18. Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells Reduces Erectile Dysfunction Following Cavernous Nerve Injury in Rats.

Matsuda Y, Sasaki M, Kataoka-Sasaki Y, Takayanagi A, Kobayashi K, Oka S, Nakazaki M, Masumori N, Kocsis JD, Honmou O.

Sex Med. 2018 Mar;6(1):49–57. doi: 10.1016/j.esxm.2017.10.005. Epub 2017 Dec 21.

PMID: 29275062 Free PMC Article

19. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.

Shindo T, Shimizu T, Nojima M, Niinuma T, Maruyama R, Kitajima H, Kai M, Itoh N, Suzuki H, Masumori N.

Urology. 2018 Mar;113:71–78. doi: 10.1016/j.urology.2017.11.025. Epub 2017 Nov 28.

PMID: 29196070

20. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.

Int J Clin Oncol. 2018 Feb;23(1):173–180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2.

PMID: 28770408 Free PMC Article

21. Efficacy of novel $\beta 3$ -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.

Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Hashimoto K, Minemura K.

Int J Urol. 2018 Dec 17. doi: 10.1111/iju.13877. [Epub ahead of print]

PMID: 30557916

22. Editorial Comment to Assessing perioperative, functional and oncological outcomes of patients with imperative versus elective indications for robot-assisted partial nephrectomy: Results from a high-volume center.

Tanaka T.

Int J Urol. 2018 Sep;25(9):831. doi: 10.1111/iju.13772. Epub 2018 Aug 13. No abstract

available.

PMID: 30103291

23. A case of ureteral obstruction and sepsis induced by bladder perforation following Intravesical bacillus Calmette–Guerin successfully treated with an antituberculous Agent, antimicrobial chemotherapy and percutaneous urine drainage, International Cancer Conference Journal 7:103–106 2018

Daichi Morooka, Naotaka Nishiyama, Yoshiki Hiyama, Naoya Masunori

24. Second transurethral resection against Ta high grade tumor : Residual location and predictive factor. A single center, retrospective study, Japanese Journal of Endourology 31, 108–112, 2018

Tetsuya Sindo, Naotaka Nishiyama, Naoya Masunori

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2017 年)

1. Surfactant Protein A Inhibits Growth and Adherence of Uropathogenic Escherichia coli To Protect the Bladder from Infection.

Hashimoto J, Takahashi M, Saito A, Murata M, Kurimura Y, Nishitani C, Takamiya R, Uehara Y, Hasegawa Y, Hiyama Y, Sawada N, Takahashi S, Masumori N, Kuroki Y, Ariki S. *J Immunol.* 2017 Apr 1;198(7):2898-2905. doi: 10.4049/jimmunol.1502626. Epub 2017 Feb 22. PMID: 28228557

2. Expression of Ku70 predicts results of radiotherapy in prostate cancer.

Hasegawa T, Someya M, Hori M, Matsumoto Y, Nakata K, Nojima M, Kitagawa M, Tsuchiya T, Masumori N, Hasegawa T, Sakata KI. *Strahlenther Onkol.* 2017 Jan;193(1):29-37. doi: 10.1007/s00066-016-1023-7. Epub 2016 Jul 27. PMID: 27465041

3. Local tumor control and DNA-PK activity of peripheral blood lymphocytes in prostate cancer patients receiving radiotherapy.

Someya M, Hasegawa T, Hori M, Matsumoto Y, Nakata K, Masumori N, Sakata KI. *J Radiat Res.* 2017 Mar 1;58(2):225-231. doi: 10.1093/jrr/rrw099. PMID: 2839957

4. Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A.

Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S. *World J Urol.* 2017 Nov;35(11):1737-1744. doi: 10.1007/s00345-017-2049-x. Epub 2017 May

15.

PMID: 28508102

5. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.

Int J Clin Oncol. 2017 Aug 2. doi: 10.1007/s10147-017-1176-0. [Epub ahead of print]

PMID: 28770408

6. The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.

Tanaka Y, Tanuma Y, Masumori N.

Adv Urol. 2017;2017:4842025. doi: 10.1155/2017/4842025. Epub 2017 Jun 13.

PMID: 28694823

7. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.

Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, Saitoh T, Sakai H, Takahashi S, Ukimura O, Yamanishi T, Yokoyama O, Yoshida M, Maeda K.

Int J Urol. 2017 Oct;24(10):716-729. doi: 10.1111/iju.13401. Epub 2017 Jul 26.

PMID: 2874857

8. Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain.

Ichihara K, Aizawa N, Akiyama Y, Kamei J, Masumori N, Andersson KE, Homma Y, Igawa Y. Pain. 2017 Aug;158(8):1538-1545. doi: 10.1097/j.pain.0000000000000947.

PMID:28595240

9. The discrepancy between serum creatinine and cystatin C can predict renal function after treatment for postrenal acute kidney injury: multicenter study and pooled data analysis.

Matsuki M, Tanaka T, Maehana T, Kyoda Y, Ichihara K, Hashimoto K, Yanase M, Matsukawa M, Adachi H, Takahashi S, Masumori N.

Clin Exp Nephrol. 2017 Oct;21(5):852-857. doi: 10.1007/s10157-016-1377-2. Epub 2017 Mar 3.

PMID: 28258496

○その他論文 (2017年)

1. 舛森直哉：尿路・性器結核、今日の治療指針 私はこうして治療している
医学書院 TODAY' THEPAPY 2017

2. 高橋聡、舛森直哉：前立腺炎症候群
1336 専門家による 私の治療 2017-18 年度版
3. 藤居賢 吉岡薫、國本雄介、清治翔伍、桧山佳樹、高橋聡、舛森直哉、宮本篤
抗菌化学療法認定薬剤師の役割と病棟専従薬剤師への支援－泌尿器科領域－
日本化学療法学会雑誌 VOL.65 NO.4 JULY2017
4. 市原浩司、舛森直哉、高橋聡
フルニエ壊疽（壊死性筋膜炎）
特集 まるごと尿路感染症と性感染症ぶらす炎症性疾患
uro-Lo 2017 vol.22 メディカ出版
5. A case of metastatic renal cell carcinoma showing complete remission after cytoreductive
Nephrectomy followed by temsirolimus
Naotaka Nishiyama, Naoya Masumiri
International Cancer Conference Journal January 2017
6. A case of metastatic renal cell carcinoma showing complete remission after
cytoreductive nephrectomy followed by temsirolimus

Naotaka Nishiyama, Naoya Masumori
Int Cnc Conf J(2017)
7. A case of cisplatin-refractory advanced pure seminoma showing complete remission
after treatment with high-dose carboplatin plus etoposide as fourth-line salvage
chemotherapy

Kimihito Tachikawa, Naotaka Nishiyama, Takashi Muranaka, Koichi Takada,
Kazuyuki Murase, Tsutomu Kouno, Kato Junji, Naoya Masumori
International Cancer Conference Journal DOI 10.2017
8. 田中俊明、前鼻健志、舛森直哉
膀胱癌尿路変更後の長期成績
第 43 回 尿路悪性腫瘍研究会記録 泌尿器科サバイバーシップ 2017 年 5 月 15 日発行
9. 水野孝祐、西中一幸、木村幸子、舛森直哉
【学会賞受賞論文】8 歳女兒に精細管内胚細胞腫瘍を認めた安全型アンドロゲン不応症候群
の 1 例 J. J. P. U. Vol26
10. 柴森康介、進藤哲哉、高柳明夫、北村寛、舛森直哉
進行性前立腺癌に対する内分泌単億療法による治療成績の検討
泌尿器外科 30 2017
11. 舛森直哉
前立腺がん 北海道の医療最前線 目指せ 100 歳 健康寿命を延ばす習慣、教えます
知っておきたい七大生活習慣病の正体 uro-ro 2017 Vol.22
12. 橋本浩平、舛森直哉
特集 まるごと 泌尿器がんの化学療法・分子標的療法・免疫療法 化学療法（ドセタキセ

ル・カバジタキセル) を用いた治療

13. 田中俊明、舛森直哉
新腎・泌尿器癌(上)ー基礎・臨床研究の進歩ー腎癌 IV 腎癌の浸潤・転移臓器別転移の実態、日本臨床 75 巻 増刊号 6 (2017 年 8 月 20 日発行)
14. 田中俊明、舛森直哉
新腎・泌尿器癌(下)ー基礎・臨床研究の進歩ー精巣癌 IV 精巣癌の治療手術療法術後合併症とその対策 日本臨床 75 巻 増刊号 7 (2017 年 10 月 20 日発行)
15. 舛森直哉
前立腺肥大症 「Year Note TOPICs2017-2018 内科・外科疾患」MEDIC NEDIA 2017
16. 舛森直哉
泌尿器系・生殖器系疾患 前立腺肥大症、循環器系・泌尿器系・生殖器系の病気とくすり薬局 2017 Vol. 68
17. 舛森直哉
男性下部尿路症状・前立腺肥大症・診療ガイドライン(作成委員) 2017 年 4 月 20 日
18. 舛森直哉
保険薬局の薬剤師が知っておくべき排尿障害治療薬について～男性下部尿路症状・前立腺肥大症診療ガイドラインを踏まえて～あすかクラブ通信 autumn 2017
19. 舛森直哉
特集 男性下部尿路症状・前立腺肥大症の疫学、改訂 男性下部尿路症状・前立腺肥大症診療ガイドライン、排尿障害プラクティス Vol. 25 No. 2 2017
20. 岡田学、前鼻健志、田中俊明、北村寛、舛森直哉
交叉性異所性融合腎に発生した腎細胞癌に対して腎部分切除術を施行した 1 例 泌尿器科紀要 63 2017
21. 田中俊明、舛森直哉
腎後性腎不全の診断と治療後経過の予測【血清シスタチン C は腎後性腎不全の治療後経過の予測に有利】週刊 日本医事新報 2017. 2. 18
22. 市原浩司、高橋聡
特集 泌尿器科感染症にかかわるエマージェンシー 旧姓腎盂腎炎 泌尿器 Care&Cure ULO-LO2017 vol22 メディカ出版
23. 前鼻健志、田中俊明、舛森直哉
腎移植後骨粗鬆症に対するテノスマブの初期治療経験 日本泌尿器科学会雑誌 2017
24. 舛森直哉
我が国における性同一性障害診断の現状と課題【適切な処置が行えるよう医術者と当事者間での正確な情報提供が重要】週刊 日本医事新報 2017.7.1
25. 舛森直哉
性同一性障害の care と cure uro-Lo 2017 Vol22 メディカ出版

26. 太刀川公人、前鼻健志、田中俊明、市原浩司、柳瀬雅裕、福澤信之、原田浩、舂森直哉
胸腺腫瘍を指摘された生体腎移植ドナー候補に対してビデオ補助胸腔鏡手術で悪性腫瘍の除外診断を行いドナー適格と判断し得た1例 日本臨床腎移植学会雑誌 Vol5 2017
27. 村中貴之、小林皇、前田俊浩、進藤哲哉、舂森直哉
札幌医科大学附属病院における腹腔鏡下根治敵膀胱摘除術の検討
Japanese Journal of Endourology 2017
28. 伊與木貴也、前鼻健志、田中俊明、山本元久、高橋裕樹、舂森直哉
特発性後腹膜線維症に対する治療成績の検討—IgG4 関連疾患の積極的診断を考慮した診断・治療プロトコールの検証— 泌尿紀要 63 2017

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2016 年)

1. Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan.
Kitamura H, Takahashi A, Takei F, Hotta H, Miyao N, Shindo T, Igarashi M, Tachiki H, Kunishima Y, Muranaka T, Shigyo M, Ikehata Y, Masumori N; Sapporo Medical University Urologic Oncology Consortium..
Anticancer Res. 2016 Oct;36(10):5531-5536.
2. Response to Re: Incidence and risk factors for acute kidney injury after radical cystectomy.
Ikehata Y, Tanaka T, Masumori N.
Int J Urol. 2016 Nov;23(11):964-965. doi: 10.1111/iju.13183. No abstract available.
PMID: 27550862
3. Changes of sexual function and perception in Japanese men: A 15-year cross-sectional community-based study.
Takayanagi A, Kobayashi K, Fukuta F, Matsuki M, Matsuda Y, Mori M, Masumori N.
Int J Urol. 2016 Nov;23(11):941-945. doi: 10.1111/iju.13184.
PMID: 27520708
4. Natural history of hematospermia in 189 Japanese men.
Furuya S, Masumori N, Takayanagi A.
Int J Urol. 2016 Nov;23(11):934-940. doi: 10.1111/iju.13176.
PMID: 27520544
5. A case of infective endocarditis and pyogenic spondylitis after transrectal ultrasound guided prostate biopsy.
Hiyama Y, Takahashi S, Uehara T, Ichihara K, Hashimoto J, Masumori N.
J Infect Chemother. 2016 Nov;22(11):767-769. doi: 10.1016/j.jiac.2016.05.002.
PMID: 27374863

6. Heat Shock Protein 90 α Is a Potential Serological Biomarker of Acute Rejection after Renal Transplantation.

Maehana T, Tanaka T, Kitamura H, Fukuzawa N, Ishida H, Harada H, Tanabe K, Masumori N.

PLoS One. 2016 Sep 15;11(9):e0162942. doi: 10.1371/journal.pone.0162942.

PMID: 27631127 Free PMC Article

7. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.

Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group..Int J Clin Oncol. 2016 Sep 10. [Epub ahead of print]

PMID: 27614621

8. Clinical significance of adding 3 Tesla MRI to the algorithm for decision making on neurovascular bundle preservation in radical prostatectomy.

Shindo T, Kitamura H, Kobayashi K, Hashimoto K, Nishida S, Tamakawa M, Kawaai Y, Masumori N.

Jpn J Clin Oncol. 2016 Aug 30. [Epub ahead of print]

PMID: 27576436

9. Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan.

Masumori N, Tsukamoto T, Shibuya A, Miyao N, Kunishima Y, Iwasawa A.

Patient Prefer Adherence. 2016 Jul 22;10:1309-16. doi: 10.2147/PPA.S110440.

PMID: 27524886 Free PMC Article

10. Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder.

Tanaka Y, Tanuma Y, Masumori N.

Int J Urol. 2016 Oct;23(10):866-872. doi: 10.1111/iju.13174.

PMID: 27520420

11. Expression of Ku70 predicts results of radiotherapy in prostate cancer.

Hasegawa T, Someya M, Hori M, Matsumoto Y, Nakata K, Nojima M, Kitagawa M, Tsuchiya T,

Masumori N, Hasegawa T, Sakata KI. Strahlenther Onkol. 2016 Jul 27. [Epub ahead of print]

PMID: 27465041

12. ationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan.

Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sato J, Hanaki H, Masumori N, Kiyota H, Egawa S, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Wada K, Kobayashi K, Matsubara A, Matsumoto T, Eto M, Tatsugami K, Kuroiwa K, Ito K, Hosobe T, Hirayama H, Narita H, Yamaguchi T, Ito S, Sumii T, Kawai S, Kanokogi M, Kawano H, Chokyu H, Uno S, Monden K, Kaji S, Kawahara M, Takayama K, Ito M, Yoshioka M, Kano M, Konishi T, Kadena H, Nishi S, Nishimura H, Yamauchi T, Maeda S, Horie M, Ihara H, Matsumura M, Shirane T, Takeyama K, Akiyama K, Takahashi K, Ikuyama T, Inatomi H, Yoh M.

J Infect Chemother. 2016 Sep;22(9):581-6. doi: 10.1016/j.jiac.2016.06.010.

PMID: 27452428

13. Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium *Slackia* sp. strain NATTS with the risk of prostate cancer: a case-control study among Japanese men.
Nagata Y, Sugiyama Y, Fukuta F, Takayanagi A, Masumori N, Tsukamoto T, Akasaka H, Ohnishi H, Saitoh S, Miura T, Moriyama K, Tsuji H, Akaza H, Mori M.
Int Urol Nephrol. 2016 Sep;48(9):1453-60. doi: 10.1007/s11255-016-1335-7.
PMID: 27262851
14. [Dosing Schedules and Outcomes in Patients Treated with First-Line Sunitinib for Advanced Renal Cell Carcinoma].
Inoue R, Kitamura H, Shindo T, Nishiyama N, Masumori N.
Hinyokika Kyo. 2016 Apr;62(4):173-7. Japanese.
PMID: 27217010
15. Incidence and risk factors for acute kidney injury after radical cystectomy.
Ikehata Y, Tanaka T, Ichihara K, Kobayashi K, Kitamura H, Takahashi S, Masumori N.
Int J Urol. 2016 Jul;23(7):558-63. doi: 10.1111/iju.13104.
PMID: 27168129
16. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts.
Kohei N, Tanaka T, Tanabe K, Masumori N, Dvorina N, Valujskikh A, Baldwin WM 3rd, Fairchild RL.
Kidney Int. 2016 Jun;89(6):1293-306. doi: 10.1016/j.kint.2016.02.030.
PMID: 27165816
17. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Taguri M, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M, Kubota Y.
Prostate. 2016 Mar;76(4):376-82. doi: 10.1002/pros.23129.
PMID: 26616365
18. Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis.
Hirobe M, Masumori N, Tanaka T, Kitamura H, Tonooka A, Hasegawa T, Tsukamoto T.
Int J Urol. 2016 Feb;23(2):140-5. doi: 10.1111/iju.13007.
PMID: 26563505
19. Genome evolution in the allotetraploid frog *Xenopus laevis*.
Session AM, Uno Y, Kwon T, Chapman JA, Toyoda A, Takahashi S, Fukui A, Hikosaka A, Suzuki A, Kondo M, van Heeringen SJ, Quigley I, Heinz S, Ogino H, Ochi H, Hellsten U, Lyons JB, Simakov O, Putnam N, Stites J, Kuroki Y, Tanaka T, Michiue T, Watanabe M, Bogdanovic O, Lister R, Georgiou G, Paranjpe SS, van Kruijsbergen I, Shu S, Carlson J, Kinoshita T, Ohta Y, Mawaribuchi S, Jenkins J, Grimwood J, Schmutz J, Mitros T, Mozaffari SV, Suzuki Y, Haramoto Y, Yamamoto TS, Takagi C, Heald R, Miller K, Haudenschild C, Kitzman J, Nakayama T, Izutsu Y, Robert J, Fortriede J, Burns K, Lotay V, Karimi K, Yasuoka Y, Dichmann DS, Flajnik MF, Houston DW, Shendure J, DuPasquier L, Vize PD, Zorn AM, Ito M, Marcotte EM, Wallingford JB, Ito Y, Asashima M, Ueno N, Matsuda Y, Veenstra GJ, Fujiyama A, Harland RM, Taira M, Rokhsar DS.
Nature. 2016 Oct 19;538(7625):336-343. doi: 10.1038/nature19840.
PMID: 27762356

20. ypoxia augments MHC class I antigen presentation via facilitation of ERO1- α -mediated oxidative folding in murine tumor cells.

Kajiwara T, Tanaka T, Kukita K, Kutomi G, Saito K, Okuya K, Takaya A, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Hirata K, Sato N, Tamura Y.

Eur J Immunol. 2016 Sep 26. doi: 10.1002/eji.201646525. [Epub ahead of print]

PMID: 27667124

21. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangiomyomatosis.

Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K.

Ann Am Thorac Soc. 2016 Nov;13(11):1912-1922.

PMID: 27513278

22. Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress.

Saijo H, Hirohashi Y, Torigoe T, Horibe R, Takaya A, Murai A, Kubo T, Kajiwara T, Tanaka T, Shionoya Y, Yamamoto E, Maruyama R, Nakatsugawa M, Kanaseki T, Tsukahara T, Tamura Y, Sasaki Y, Tokino T, Suzuki H, Kondo T, Takahashi H, Sato N.

Oncotarget. 2016 Jul 13. doi: 10.18632/oncotarget.10571. [Epub ahead of print]

PMID: 27418136 Free Article

23. Cancer-associated oxidoreductase ERO1- α drives the production of VEGF via oxidative protein folding and regulating the mRNA level.

Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Okamoto Y, Hirata K, Sato N, Tamura Y.

Br J Cancer. 2016 May 24;114(11):1227-34. doi: 10.1038/bjc.2016.105.

PMID: 27100727

24. Systematic molecular analyses of SHOX in Japanese patients with idiopathic short stature and Leri-Weill dyschondrosteosis.

Shima H, Tanaka T, Kamimaki T, Dateki S, Muroya K, Horikawa R, Kanno J, Adachi M, Naiki Y, Tanaka H, Mabe H, Yagasaki H, Kure S, Matsubara Y, Tajima T, Kashimada K, Ishii T, Asakura Y, Fujiwara I, Soneda S, Nagasaki K, Hamajima T, Kanzaki S, Jinno T, Ogata T, Fukami M; Japanese SHOX study group..

J Hum Genet. 2016 Jul;61(7):585-91. doi: 10.1038/jhg.2016.18.

PMID: 26984564

25. aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.

Nature. 2016 May 23;534(7607):402-6. doi: 10.1038/nature18294.

PMID: 27281199

26. The Metabotropic Glutamate Receptor Subtype 1 Mediates Experience-Dependent Maintenance of Mature Synaptic Connectivity in the Visual Thalamus.

Narushima M, Uchigashima M, Yagasaki Y, Harada T, Nagumo Y, Uesaka N, Hashimoto K, Aiba A, Watanabe M, Miyata M, Kano M.

Neuron. 2016 Sep 7;91(5):1097-109. doi: 10.1016/j.neuron.2016.07.035.

PMID: 27545713

27. Ionic Basis for Membrane Potential Resonance in Neurons of the Inferior Olive.

Matsumoto-Makidono Y, Nakayama H, Yamasaki M, Miyazaki T, Kobayashi K, Watanabe M, Kano M, Sakimura K, Hashimoto K.

Cell Rep. 2016 Jul 26;16(4):994-1004. doi: 10.1016/j.celrep.2016.06.053.

PMID: 27425615 Free Article

28. Territories of heterologous inputs onto Purkinje cell dendrites are segregated by mGluR1-dependent parallel fiber synapse elimination.

Ichikawa R, Hashimoto K, Miyazaki T, Uchigashima M, Yamasaki M, Aiba A, Kano M, Watanabe M.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2282-7. doi: 10.1073/pnas.1511513113.

PMID: 26858447 Free PMC Article

PMID: 27798926

○その他論文 (2016 年)

1. A case of infective endocarditis and pyogenic spondylitis after transrectal ultrasound Guided prostate biopsy.

Yoshiki Hiyama, Satoshi Takahashi, Teruhisa Uehara, Koji Ichihara, Jiro Hashimoto, Naoya, Masumori:

Journal of Infection and Chemotherapy. 1-3,2016

2. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from. Male urethritis in Japan. Satoshi Takahashi, Ryoichi Hamusuna, Mitsuru Yasuda, Kiyohito Ishikawa, Hirshi Hayami, Shinya Uehara, Shingo Yamamoto, Shinichi Minamitani, Junichi Kadota, Satoshi Iwata, Mitsuo Kaku, Akira Watanabe, Junko Sato, Hideaki Hanaki, Naoya Masumori, Hiroshi Kiyota, Kanao Kobayashi, Akio Matsubara, Tetsuro Matsumoto, Masatoshi Eto, Katsunori Tatsugami, Kentaro Kuroiwa, Kenji Ito, Toru Sumii, Shunichi Kawai, Mototsugu Kanokoogi, Motoshi Kawahara, Kzuo Takayama, Masayasu Ito, Masaru Yoshida, Motonori Kano, Shinichi Konishi, Hitoshi Kadena, Shohei Nishi, Hirofumi Nishimura, Takeshi Shirane, Koh Takeyama, Kikuo Akiyama, Koichi Takahashi, Toshihiro Ikuyama, Hisao Inatomi, Mutsumasa Yoh: Journal of Infection and Chemotherapy.1-6,2016

3. 桧山佳樹、市原浩司、高橋聡：特集=泌尿器疾患の治療戦略、気腫性腎盂腎炎の治療戦略、MEDICANENT NEWS 第 2227 号、2016 年 4 月 5 日

4. 市原浩司、高橋聡、舛森直哉：糖尿に伴う下部尿路機能障害と尿路感染症、日本化学療法学会雑誌 VOL.64 NO.5 SEPT. 2016

5. 太刀川公人、桧山佳樹、市原浩司、高橋聡、関根利佳、山蔭道明、舛森直哉：間質性膀胱炎に対する両側仙骨神経根ブロックが著効した 1 例、泌尿器外科 29; 173-176, 2016

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2015 年)

1. Takayanagi A, Sasaki M, Kataoka-Sasaki Y, Kobayashi K, Matsuda Y, Oka S, Masumori N, Kocsis JD, Honmou O.
Intravenous Preload of Mesenchymal Stem Cells Rescues Erectile Function in a Rat Model of Cavernous Nerve Injury.
J Sex Med. 2015 Aug;12(8):1713-21. doi: 10.1111/jsm.12957. Epub 2015 Jul 24.
2. Kojima T, Kawai K, Tsuchiya K, Abe T, Shinohara N, Tanaka T, Masumori N, Yamada S, Arai Y, Narita S, Tsuchiya N, Habuchi T, Nishiyama H.
Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Int J Urol. 2015 Oct;22(10):923-7. doi: 10.1111/iju.12844. Epub 2015 Jun 18.
3. Kitamura H, Takahashi A, Hotta H, Kato R, Kunishima Y, Takei F, Horita H, Masumori N; Sapporo Medical University Urologic Oncology Consortium.
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Int J Urol. 2015 Oct;22(10):911-4. doi: 10.1111/iju.12842. Epub 2015 Jun 18.
4. Akutsu N, Adachi Y, Isosaka M, Mita H, Takagi H, Sasaki S, Yamamoto H, Arimura Y, Ishii Y, Masumori N, Endo T, Shinomura Y.
Mediastinal Yolk Sac Tumor Producing Protein Induced by Vitamin K Absence or Antagonist-II.
Intern Med. 2015;54(12):1531-6. doi: 10.2169/internalmedicine.54.4025. Epub 2015 Jun 15.
5. Kurimura Y, Takahashi S, Hiyama Y, Uehara T, Ichihara K, Hashimoto J, Nishiyama N, Kitamura H, Masumori N.
[Significance of Procalcitonin Measurement in Cases with Febrile Condition during Chemotherapy for Urological Cancer].
Hinyokika Kyo. 2015 Apr;61(4):141-5. Japanese.

6. Inoue R, Kitamura H, Shindo T, Yanase M, Takahashi A, Miyao N, Ito N, Hotta H, Hirose T, Taguchi K, Matsukawa M, Uehara T, Kunishima Y, Hotta H, Masumori N.
[Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma].
Hinyokika Kyo. 2015 Apr;61(4):135-9. Japanese.
7. Shindo T, Hashimoto K, Shimizu T, Itoh N, Masumori N.
Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
Korean J Urol. 2015 Apr;56(4):305-9. doi: 10.4111/kju.2015.56.4.305. Epub 2015 Mar 27.
8. Fukuta F, Kitamura H, Yanase M, Taguchi K, Takahashi A, Kunishima Y, Miyake M, Adachi H, Itoh N, Hirose T, Takagi S, Miyao N, Matsukawa M, Shigyo M, Masumori N.
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Jpn J Clin Oncol. 2015 Jul;45(7):682-7. doi: 10.1093/jjco/hyv053. Epub 2015 Apr 10.
9. Masumori N.
Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Int J Urol. 2015 Jun;22(6):589. doi: 10.1111/iju.12765. Epub 2015 Mar 31. No abstract available.
10. Takahashi S, Ichihara K, Hashimoto K, Hiyama Y, Muranaka T, Hashimoto J, Fukuta F, Kobayashi K, Niiyama Y, Yamakage M, Masumori N.
Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy.
J Infect Chemother. 2015 Jun;21(6):464-7. doi: 10.1016/j.jiac.2015.03.001. Epub 2015 Mar 12.
11. Nishiyama N, Takahashi S, Mizuno T, Uehara T, Hashimoto J, Kurimura Y, Masumori N.
Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
Int J Clin Oncol. 2015 Oct;20(5):1012-7. doi: 10.1007/s10147-015-0787-6. Epub 2015 Feb 5.
12. Masumori N.
Reply: To PMID 25623712.
Urology. 2015 Feb;85(2):435. doi: 10.1016/j.urology.2014.09.048. No abstract available.
13. Hashimoto K, Mizuno T, Kitamura H, Shindo T, Takahashi S, Masumori N.
The primary local stage at diagnosis predicts regional symptoms caused by local progression in patients with castration-resistant prostate cancer.
Urology. 2015 Feb;85(2):430-5. doi: 10.1016/j.urology.2014.09.044.
14. Hashimoto K, Kyoda Y, Tanaka T, Maeda T, Kobayashi K, Uchida K, Kitamura H, Hirata K, Tsukamoto T, Masumori N.
The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.
Lab Invest. 2015 Mar;95(3):283-95. doi: 10.1038/labinvest.2014.165. Epub 2015 Jan 12.

15. Nishida S, Hirohashi Y, Torigoe T, Nojima M, Inoue R, Kitamura H, Tanaka T, Asanuma H, Sato N, Masumori N.
Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy.
Anticancer Res. 2015 Jan;35(1):413-8.
16. Yamamoto T, Takahashi S, Ichihara K, Hiyama Y, Uehara T, Hashimoto J, Hirobe M, Masumori N.
How do we understand the disagreement in the frequency of surgical site infection between the CDC and Clavien-Dindo classifications?
J Infect Chemother. 2015 Feb;21(2):130-3. doi: 10.1016/j.jiac.2014.10.016. Epub 2014 Nov 11.
17. Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y.
A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
J Urol. 2015 Mar;193(3):921-6. doi: 10.1016/j.juro.2014.09.091. Epub 2014 Sep 22.
18. Takahashi S, Ichihara K, Hiyama Y, Uehara T, Hashimoto J, Masumori N.
Do patients who complain of lower urinary tract symptoms frequently have clinically significant pyuria?
J Infect Chemother. 2015 Jan;21(1):31-3. doi: 10.1016/j.jiac.2014.08.022. Epub 2014 Sep 12.
19. Ishikawa K, Hamasuna R, Uehara S, Yasuda M, Yamamoto S, Hayami H, Takahashi S, Matsumoto T, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Deguchi T, Matsumoto M, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Wakeda H, Amemoto Y, Onodera S, Goto H, Komeda H, Yamashita M, Takenaka T, Fujimoto Y, Tsugawa M, Takahashi Y, Maeda H, Onishi H, Ishitoya S, Nishimura K, Mitsumori K, Ito T, Togo Y, Nakamura I, Ito N, Kanamaru S, Hirose T, Muranaka T, Yamada D, Ishihara S, Oka H, Inatomi H, Matsui T, Kobuke M, Kunishima Y, Kimura T, Ichikawa T, Kagara I, Matsukawa M, Takahashi K, Mita K, Kato M, Okumura K, Kawanishi H, Hashimura T, Aoyama T, Shigeta M, Koda S, Taguchi K, Matsuda Y.
Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
J Infect Chemother. 2015 Sep;21(9):623-33. doi: 10.1016/j.jiac.2015.05.014. Epub 2015 Jun 9.
20. Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, Kamba T, Kato M, Nakai Y, Furuse H, Kume H, Ide H, Kitamura H, Yokomizo A, Kimura T, Tomita Y, Ohno K, Kakehi Y.
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Int J Clin Oncol. 2015 Oct;20(5):1026-34. doi: 10.1007/s10147-015-0820-9. Epub 2015 Mar 26.
21. Matsuda Y, Hisasue S, Kumamoto Y, Kobayashi K, Hashimoto K, Sato Y, Masumori N.
Correlation between erection hardness score and nocturnal penile tumescence measurement.
J Sex Med. 2014 Sep;11(9):2272-6. doi: 10.1111/jsm.12617. Epub 2014 Jun 12.
22. Ichihara K, Masumori N, Takahashi S, Miyao N, Kato R.
Bladder Neck Rupture and Vesicovaginal Fistula Associated with Pelvic Fracture in Female.
Low Urin Tract Symptoms. 2015 May;7(2):115-7. doi: 10.1111/luts.12056. Epub 2014 Mar 24.

○その他論文 (2015 年)

1. 舩森 直哉
性分化疾患 (内分泌)
「今日の治療指針」Vol. 57、山口 徹、北原光夫監修、pp.1106-1107、医学書院、2015.
2. 舩森 直哉
前立腺肥大症(BPH)
『Year Note TOPICS 2015-2016 内科・外科疾患』5th edition 212-213, 2015.
3. 北村 寛、小林 皇、舩森 直哉
TURBT の手技と機器—Conventional TURBT— (泌尿器科)
泌尿器外科 28; 135-138, 2015.
4. 舩森 直哉
腎細胞癌診療の話題と将来展望(Oncology)
RCC Today 13; 12-4, 2015.
5. 舩森 直哉、市原 浩司
排尿障害—排尿困難の病理と治療
遥か 9; 45-50, 2014.
6. 桧山 佳樹、高橋 聡
尿路生殖器感染症 (尿路感染症・性感染症) に用いる薬(STD)
泌尿器ケア 20; 263-269, 2015.
7. 高橋 聡、市原 浩司
〈II. LUTS の原因疾患を治す〉慢性前立腺炎／慢性骨盤痛症候群(BPH)
「LUTS 診療ロードマップ」高橋 悟編集、pp.142-146、メジカルビュー社、2015.
8. 福多 史昌、舩森 直哉
〈II. LUTS の原因疾患を治す〉前立腺肥大症 (男性) (BPH)
「LUTS 診療ロードマップ」高橋 悟編集、pp.193-203、メジカルビュー社、2015.
9. 〈6. 内分泌疾患 (精巣機能障害)〉加齢男性性腺機能低下症候群 (LOH 症候群) (性機能)
小林 皇、舩森 直哉
臨床泌尿器科 69 増刊号 (泌尿器科外来 パーフェクトガイド) ; 221-223, 2015.
10. 小林 皇、舩森 直哉
〈9. 尿路・性器損傷と膀胱異物〉陰茎折症 (泌尿器科)
臨床泌尿器科 69 増刊号 (泌尿器科外来 パーフェクトガイド) ; 278-281, 2015.
11. Okabe K, Kitamura H, Nishiyama N and Masumori N
A case of chromophobe renal cell carcinoma in a 12-year-old girl.(Oncology)
Int Canc Conf J: DOI 10.107/s13691-015-0221-y.

12. 市原 浩司、舛森 直哉
＜泌尿器 診療 Q&A＞ Q: BPH 診療 ($\alpha 1$ ブロッカー) に OAB 治療 (抗コリン薬) を追加したとき、尿閉をきたして困ったことがあります。抗コリン薬を併用する可否の判断基準を教えてください。(BPH)
LUTS PLAZZA Vol.2 (No.1):12、2015 春.
13. Fukuta F, Masumori N
A review of naftopidil for treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Curr Bladder Dysfunct Rep; DOI 10.1007/s11884-015-0293-8
14. 前立腺肥大症治療薬デュタステリド (BPH)
進藤 哲哉、舛森 直哉
泌尿器ケア 20; 107-111, 2015.
15. (司会) 舛森 直哉、(討論者) 古屋 聖兒、山口 秋人、平山 暁秀
＜座談会＞手術でよくなる肥大症、よくなるしない肥大症(BPH)
Prostate Journal 2; 135-142, 2015.
16. 市原 浩司、舛森 直哉
女性尿道再建術 (泌尿器科)
泌尿器外科 28; 443-448, 2015.
17. 北村 寛
Ⅲ. 腎癌 5. 分子標的薬時代の M1 症例に対する原発巣摘除の意義は? (Oncology)
「EBM 泌尿器疾患の治療」2015-2016 edition、後藤百万、小川 修、笈 善行、出口 隆、宮澤克人編、中外医学社、東京、pp.186-190、2015.
18. 舛森 直哉
Ⅳ. 下部尿路機能障害 2. 前立腺肥大症に対する $\alpha 1$ 遮断薬、 5α 還元酵素阻害薬の使い分けは? (PBH)
「EBM 泌尿器疾患の治療」2015-2016 edition、
後藤百万、小川 修、笈 善行、出口 隆、宮澤克人編、中外医学社、東京、pp.288-293、2015.
19. 西山 直隆、進藤 哲哉、堀田 裕、高橋 敦、柳瀬 雅裕、伊藤 直樹、立木 仁、尾 則臣、松川 雅則、国島 康晴、田口 圭介、北村 寛、舛森 直哉
BCG 膀胱内注入療法を施行した筋層非浸潤性膀胱癌 (NMIBC) の上部尿路再発に関する後ろ向き・多施設共同研究 (Oncology)
泌尿器外科 28; 360-361, 2015.
20. 前田 俊浩、舛森 直哉
男性不妊症 (内分泌)
泌尿器外科 28 (特別号 後期研修医がおさえておきたい泌尿器疾患アトラス) 192-195, 2015.
21. 栗村 雄一郎、高橋 聡、桧山 佳樹、上原 央久、市原 浩司、橋本 次朗、西山 直隆、北村 寛、舛森 直哉
泌尿器科領域抗癌化学療法中の発熱に対するプロカルシトニン測定の意義 (感染症)
泌尿紀要 61; 141-145, 2015.

22. 京田 有樹、舛森 直哉
前立腺がんと前立腺肥大症の関係(BPH)
臨床と研究 92; 538-541, 2015.
23. 井上隆太、北村 寛、進藤哲哉、舛森 直哉ほか<札幌医科大学泌尿器癌コンソーシアム>
転移性淡明腎細胞癌に対する分子標的薬の効果と予後因子の検討(Oncology)
泌尿紀要 61; 135-139, 2015.
24. 田端 秀敏、西中 一幸、舛森 直哉
小児傍尿管憩室に伴う膀胱尿管逆流症の外科手術—膀胱外再建術の安全性、有効性の検討—
(泌尿器科)
日小外会誌 51; 813-817, 2015.
25. 北村 寛、舛森 直哉
<高齢者の腎泌尿器疾患—高齢者の泌尿器癌> 腎細胞癌(Oncology)
腎と透析 78; 910-915, 2015.
26. 舛森 直哉
膿尿、細菌尿(感染症)
『今日の診断指針 第7版』金澤一郎、永井良三総編集、医学書院、pp.417-418, 2015.
27. 岡田 学、高柳 明夫、野藤 誓亮、松木 雅裕、松田 洋平、小林 皇、舛森 直哉
金属リングによる陰囊絞扼症の1例(性功能)
日本性機能学会誌 30; 9-13, 2015.
28. 北村 寛、舛森 直哉
泌尿器科からみた骨盤解剖—神経系を中心に(泌尿器科)
手術 69; 1231-1236, 2015.
29. Matsuki M, Tanaka T, Maehana T, Ichihara K, Yanase M, Matsukawa M, Adachi H, Takahashi S,
Masumori N
Serum cystatin C can be used as a marker of renal function even in patients with intestinal
urinary diversion (泌尿器科)
Asian Journal of Urology 2; 167-169, 2015.
30. 市原 浩司、高橋 聡
膿腎症(感染症)
臨床泌尿器科 69(増刊号 泌尿器科外来パーフェクトガイド); 25-27, 2015.
31. Kyoda Y, Kobayashi K, Hirobe M, Shindo T, Fukuta F, Hashimoto K, Tanaka T, Tonooka A,
Kitamura H, Takahashi S, Masumori N, Hasegawa T, Tsukamoto T.
Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis
of cancer deaths occurring more than 10 years after initial treatment.
Int J Clin Oncol. 2014 Feb;19(1):146-51.doi:10.1007/s10147-013-0533-x. Epub 2013 Feb 13.
32. 加藤 秀一、舛森 直哉
尿道外傷の観血的尿道再建術の成績(泌尿器科)
泌尿器外科 28; 1803-1807, 2015.

33. 北村 寛、吉岡 薫、舛森 直哉
＜Topics of RCC＞ 2. 各論—長期投与を目指した AE マネジメント—(Oncology)
- 3) テムシロリムス・エベロリムス
「Year Book of RCC 2015」 富田善彦、金山博臣、上村天受、篠原信雄編集、pp.89-98、
メディカルレビュー社、2015.
34. 西山 直隆、北村 寛、井上 隆太、前田 俊浩、舛森 直哉
転移性腎細胞癌に対するエベロリムスの使用成績—単-施設後ろ向き観察研究-(Oncology)
泌尿器外科 20; 1921-1925, 2015.

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2014 年)

1. [Yamamoto T](#)¹, [Takahashi S](#)², [Ichihara K](#)³, [Hiyama Y](#)³, [Uehara T](#)³, [Hashimoto J](#)³, [Hirobe M](#)³, [Masumori N](#)³.
How do we understand the disagreement in the frequency of surgical site infection between the CDC and Clavien-Dindo classifications?
[J Infect Chemother](#). 2014 Nov 11. pii: S1341-321X(14)00390-0. doi: 10.1016/j.jiac.2014.10.016. [Epub ahead of print]
2. [Takeuchi M](#)¹, [Masumori N](#)¹, [Tsukamoto T](#)¹.
Ureteral reconstruction with bowel segments: experience with eight patients in a single institute.
[Korean J Urol](#). 2014 Nov;55(11):742-9. doi: 10.4111/kju.2014.55.11.742. Epub 2014 Nov 10.
3. [Ichihara K](#)¹, [Masumori N](#)², [Fukuta F](#)¹, [Tsukamoto T](#)¹, [Iwasawa A](#)³, [Tanaka Y](#)⁴.
A Randomized Controlled Study to Evaluate the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron in Patients with Overactive Bladder Induced by Benign Prostatic Obstruction.
[J Urol](#). 2014 Sep 22. pii: S0022-5347(14)04488-7. doi: 10.1016/j.juro.2014.09.091. [Epub ahead of print]
4. [Horiguchi H](#)¹, [Takada K](#)², [Kamihara Y](#)², [Ibata S](#)², [Iyama S](#)², [Sato T](#)², [Hayashi T](#)², [Miyanishi K](#)², [Sato Y](#)², [Takimoto R](#)², [Kobune M](#)², [Kobayashi K](#)³, [Hirayama Y](#)⁴, [Masumori N](#)³, [Hasegawa T](#)⁵, [Kato J](#)².
Radiation-induced leiomyosarcoma of the prostate after brachytherapy for prostatic adenocarcinoma.
[Case Rep Oncol](#). 2014 Aug 16;7(2):565-70. doi: 10.1159/000366294. eCollection 2014.
5. [Takahashi S](#)¹, [Ichihara K](#)², [Hiyama Y](#)², [Uehara T](#)², [Hashimoto J](#)², [Masumori N](#)².
Do patients who complain of lower urinary tract symptoms frequently have clinically significant pyuria?
[J Infect Chemother](#). 2014 Sep 11. pii: S1341-321X(14)00305-5. doi: 10.1016/j.jiac.2014.08.022. [Epub ahead of print]

6. [Nishiyama N](#)¹, [Kitamura H](#)², [Hotta H](#)³, [Takahashi A](#)⁴, [Yanase M](#)⁵, [Itoh N](#)⁶, [Tachiki H](#)⁷, [Miyao N](#)⁸, [Matsukawa M](#)⁹, [Kunishima Y](#)¹⁰, [Taguchi K](#)¹¹, [Masumori N](#)².
Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
[Jpn J Clin Oncol](#). 2014 Nov;44(11):1101-8. doi: 10.1093/jjco/hyu119. Epub 2014 Aug 19.
7. [Kitamura H](#)¹, [Maeda T](#)², [Tanaka T](#)², [Fukuta F](#)², [Kobayashi K](#)², [Nishiyama N](#)², [Takahashi S](#)², [Masumori N](#)².
Comparison of laparoscopic, hand-assisted, and open surgical nephroureterectomy.
[JLS](#). 2014 Apr-Jun;18(2):288-93. doi: 10.4293/108680813X13794522666842.
8. [Matsuda Y](#)¹, [Hisasue SI](#), [Kumamoto Y](#), [Kobayashi K](#), [Hashimoto K](#), [Sato Y](#), [Masumori N](#).
Correlation between Erection Hardness Score and Nocturnal Penile Tumescence Measurement.
[J Sex Med](#). 2014 Jun 12. doi: 10.1111/jsm.12617. [Epub ahead of print]
9. [Takeuchi M](#)¹, [Hisasue SI](#), [Hashimoto K](#), [Tsukamoto T](#), [Masumori N](#).
Impact of visceral fat ratio on sleep-related erection: A retrospective study of elderly patients.
[Int J Urol](#). 2014 Jun 3. doi: 10.1111/iju.12497. [Epub ahead of print]
10. [Kitamura H](#)¹, [Tsukamoto T](#)², [Shibata T](#)³, [Masumori N](#)², [Fujimoto H](#)⁴, [Hirao Y](#)⁵, [Fujimoto K](#)⁵, [Kitamura Y](#)⁶, [Tomita Y](#)⁷, [Tobisu K](#)⁸, [Niwakawa M](#)⁸, [Naito S](#)⁹, [Eto M](#)¹⁰, [Kakehi Y](#)¹¹; [Urologic Oncology Study Group of the Japan Clinical Oncology Group](#).
Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
[Ann Oncol](#). 2014 Jun;25(6):1192-8. doi: 10.1093/annonc/mdu126. Epub 2014 Mar 24.
11. [Yamamoto T](#)¹, [Kitamura H](#), [Masumori N](#).
Complete response to interferon-alpha in a patient with metastatic renal cell carcinoma after unsuccessful molecular-targeted therapies.
[Int J Urol](#). 2014 Aug;21(8):839-40. doi: 10.1111/iju.12434. Epub 2014 Mar 17.
12. [Uehara T](#)¹, [Takahashi S](#)², [Ichihara K](#)¹, [Hiyama Y](#)¹, [Hashimoto J](#)¹, [Kurimura Y](#)¹, [Masumori N](#)¹.
Surgical site infection of scrotal and inguinal lesions after urologic surgery.
[J Infect Chemother](#). 2014 Mar;20(3):186-9. doi: 10.1016/j.jiac.2013.10.002. Epub 2013 Dec 11.
13. [Masumori N](#)¹, [Tsukamoto T](#).
Risk factors for the development of well leg compartment syndrome after sex reassignment surgery in patients with gender identity disorder.
[Int J Urol](#). 2014 Jun;21(6):623-4. doi: 10.1111/iju.12353. Epub 2013 Nov 28.
14. [Shindo T](#)¹, [Masumori N](#), [Kitamura H](#), [Tanaka T](#), [Fukuta F](#), [Hasegawa T](#), [Yanase M](#), [Miyake M](#), [Miyao N](#), [Takahashi A](#), [Matsukawa M](#), [Taguchi K](#), [Shigyo M](#), [Kunishima Y](#), [Tachiki H](#), [Tsukamoto T](#).
Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical

University Urologic Oncology Consortium (SUOC).

[World J Urol](#). 2014 Oct;32(5):1281-5. doi: 10.1007/s00345-013-1205-1. Epub 2013 Nov 5.

15. [Mizukami N](#)¹, [Yamauchi M](#)², [Koike K](#)³, [Watanabe A](#)², [Ichihara K](#)⁴, [Masumori N](#)⁴, [Yamakage M](#)².

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.

[J Pain Symptom Manage](#). 2014 Mar;47(3):542-50. doi: 10.1016/j.jpainsymman.2013.05.003. Epub 2013 Jul 12.

16. [Kyoda Y](#)¹, [Kobayashi K](#), [Hirobe M](#), [Shindo T](#), [Fukuta F](#), [Hashimoto K](#), [Tanaka T](#), [Tonooka A](#), [Kitamura H](#), [Takahashi S](#), [Masumori N](#), [Hasegawa T](#), [Tsukamoto T](#).

Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment.

[Int J Clin Oncol](#). 2014 Feb;19(1):146-51. doi: 10.1007/s10147-013-0533-x. Epub 2013 Feb 13.

17. [Ichihara K](#)¹, [Masumori N](#), [Kitamura H](#), [Hasegawa T](#), [Tsukamoto T](#).

Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens.

[Int J Clin Oncol](#). 2014 Feb;19(1):152-6. doi: 10.1007/s10147-012-0508-3. Epub 2012 Dec 19.

18. [Muranaka T](#)¹, [Takahashi S](#)², [Hirose T](#)¹, [Hattori A](#)³.

Urethral polyp-like lesions on prostatic urethra caused by Chlamydia trachomatis infection: A case report.

[J Infect Chemother](#). 2014 Nov;20(11):726-8. doi: 10.1016/j.jiac.2014.07.002. Epub 2014 Aug 14.

19. [Takahashi S](#).

Editorial Comment from Dr Takahashi to Development and validation of a nomogram predicting recurrence risk in women with symptomatic urinary tract infection.

[Int J Urol](#). 2014 Sep;21(9):934-5. doi: 10.1111/iju.12478. Epub 2014 May 5.

20. [Togo Y](#)¹, [Kubo T](#)², [Taoka R](#)³, [Hiyama Y](#)⁴, [Uehara T](#)⁴, [Hashimoto J](#)⁴, [Kurimura Y](#)⁴, [Takahashi S](#)⁴, [Tsukamoto T](#)⁴, [Miyazaki J](#)⁵, [Nishiyama H](#)⁵, [Kira S](#)⁶, [Kiyota H](#)⁶, [Yazawa S](#)⁷, [Niwa N](#)⁷, [Hongo H](#)⁷, [Oya M](#)⁷, [Kato T](#)⁸, [Yasuda M](#)⁸, [Deguchi T](#)⁸, [Ishikawa K](#)⁹, [Hoshinaga K](#)⁹, [Matsumoto M](#)¹⁰, [Shigemura K](#)¹⁰, [Tanaka K](#)¹⁰, [Arakawa S](#)¹⁰, [Fujisawa M](#)¹⁰, [Wada K](#)¹¹, [Uehara S](#)¹¹, [Watanabe T](#)¹¹, [Kumon H](#)¹¹, [Kobayashi K](#)¹², [Matsubara A](#)¹², [Matsumoto M](#)¹³, [Sho T](#)¹³, [Hamasuna R](#)¹³, [Matsumoto T](#)¹³, [Hayami H](#)¹⁴, [Nakagawa M](#)¹⁵, [Yamamoto S](#)³.

Occurrence of infection following prostate biopsy procedures in Japan: Japanese Research Group for Urinary Tract Infection (JRGU) - a multi-center retrospective study.

[J Infect Chemother](#). 2014 Apr;20(4):232-7. doi: 10.1016/j.jiac.2013.10.003. Epub 2013 Dec 11.

21. [Hamasuna R](#)¹, [Tanaka K](#)², [Hayami H](#)³, [Yasuda M](#)⁴, [Takahashi S](#)⁵, [Kobayashi K](#)⁶, [Kiyota H](#)⁷, [Yamamoto S](#)⁸, [Arakawa S](#)⁹, [Matsumoto T](#)¹⁰; [Japanese Research Group for UTI \(JRGU\)](#).

Treatment of acute uncomplicated cystitis with faropenem for 3 days versus 7 days: multicentre, randomized, open-label, controlled trial.

[J Antimicrob Chemother.](#) 2014 Jun;69(6):1675-80. doi: 10.1093/jac/dku014. Epub 2014 Feb 6.

22. [Takahashi S.](#)

Editorial comment to "Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin".

[Int J Urol.](#) 2014 Jan;21(1):107. doi: 10.1111/iju.12197. Epub 2013 May 12.

23. [Abe T](#)¹, [Kitamura H](#)², [Obara W](#)³, [Matsumura N](#)⁴, [Tsukamoto T](#)², [Fujioka T](#)³, [Hara I](#)⁴, [Murai S](#)⁵, [Shinohara N](#)⁵, [Nonomura K](#)⁵.

Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan.

[J Urol.](#) 2014 Apr;191(4):932-6. doi: 10.1016/j.juro.2013.11.004. Epub 2013 Nov 7.

24. [Kitamura H.](#)

Editorial Comment from Dr Kitamura to Cystectomy and urinary diversion as management of treatment-refractory benign disease: the impact of preoperative urological conditions on perioperative outcomes.

[Int J Urol.](#) 2014 Apr;21(4):387. doi: 10.1111/iju.12291. Epub 2013 Sep 30.

25. [Tanaka T.](#)

Editorial comment to prediction of partial nephrectomy outcomes by using the diameter-axis-polar nephrometry score.

[Int J Urol.](#) 2014 May;21(5):446-7. doi: 10.1111/iju.12369. Epub 2013 Dec 5.

○その他論文 (2014 年)

1. BCG Relapsing をきたした筋層非浸潤性膀胱癌 (NMIBC) 症例の予後に関する後ろ向き・多施設共同研究

西山 直隆、進藤 哲哉、堀田 裕、高橋 敦、柳瀬 雅裕、伊藤 直樹、立木 仁、宮尾 則臣、松川 雅則、国島 康晴、田口 圭介、北村 寛、舛森 直哉
[泌尿器外科](#) 27: 346-347, 2014.

2. 骨盤内悪性腫瘍に対する前立腺・尿路合併切除と再建術

舛森 直哉

[手術](#) 68: 743-748, 2014.

3. 市民公開講座における前立腺がん検診理解度調査の結果報告

市原 浩司、舛森 直哉

[Prostate Journal](#) 1: 153-157, 2014.

4. XIV-3 前立腺肥大症 前立腺肥大症診療ガイドライン (2011)

舛森 直哉

『診療ガイドライン UP-T0-DATE 2014-2015』門脇 孝、小室一成、宮地良樹監修、pp. 778-782, [メディカルレビュー](#)、2014.

5. 前立腺肥大症と male LUTS のコンセプトと診断・治療法の変化

舛森 直哉

[泌尿器外科](#) 27: 425-430, 2014.

6. 前立腺肥大症
舛森 直哉
『プライマリ・ケア医のための LUTS 診療ハンドブック』後藤百万編著、pp. 78-89,
中外医学社、2014.
7. 〈前立腺癌の診療ナビゲーション II. 前立腺癌の診断〉PSA 値に異常が認められた場合の
検査 直腸診
北村 寛
臨床泌尿器科 68 (増刊号) ; 54-56, 2014.
8. 前立腺肥大症
舛森 直哉
『今日の診療のために ガイドライン外来診療 2014』泉 孝英編集、pp. 368-372,
日経メディカル、2014.
9. 〈IV 全身化学療法・その他〉総論
舛森 直哉
『腎盂・尿管癌 診療ガイドライン 2014 年版』日本泌尿器科学会編、p. 59-62
10. 〈前立腺癌の診療ナビゲーション II. 前立腺癌の診断〉PSA 値に異常が認められた場合の
検査 前立腺超音波検査
北村 寛
臨床泌尿器科 68 (増刊号) ; 57-59, 2014.
11. 分子標的療法の導入により腎癌骨転移の治療成績は向上したか？
北村 寛、井上 隆太、広部 恵美、京田 有樹、田中 俊明、舛森 直哉
泌尿器外科 27 (別冊) ; 93-95, 2014.
12. Xp11.2 translocation renal cell carcinoma の臨床病理学的検討
広部 恵美、舛森 直哉、田中 俊明、北村 寛、外岡 暁子、長谷川 匡、
塚本 泰司
泌尿器外科 27 (別冊) ; 14-16, 2014.
13. 急性腎盂腎炎の変遷と今後の対応
高橋 聡
泌尿器外科 27 (臨増) ; 635-636, 2014.
泌尿紀要 54; 741-743, 2008.
14. 〈急性感染症における実践的な抗菌薬の使い方〉 尿路感染症および性感染症
高橋 聡
感染と抗菌薬 17; 174-178, 2014.
15. 〈泌尿器科領域におけるトラブルシューティング〉 ドレナージに関するトラブル回避
高橋 聡、舛森 直哉
泌尿器外科 27; 1119-1121, 2014.
16. 腹腔鏡下腎尿管全摘除術の予後因子：膀胱内再発を含めて
北村 寛、舛森 直哉
Jpn J Endourology 27; 258-261, 2014.

17. 性感染症のクリニカル・パール ―泌尿器科医のための尿道炎の臨床専門知識―
高橋 聡
臨床泌尿器科 68; 964-968, 2014.
18. 〈前立腺肥大症の薬物療法を再考する〉
舛森 直哉
Prostate Journal 1; 239, 2014.
19. 〈前立腺肥大症の薬物療法を再考する〉2. α 1 遮断薬の有用性と限界
福多 史昌、舛森 直哉
Prostate Journal 1; 245-251, 2014.
20. 〈感染症診療 update Ⅲ章. 主要な感染症 B. グラム陰性球菌感染症〉 淋菌感染症
高橋 聡
日本医師会雑誌 143 (特別号); S290-S291, 2014.
21. 〈感染症診療 update Ⅱ章. 主要な臓器感染症 L. 尿路感染症〉膀胱炎 (単純性・複雑性)、
無症候性細菌尿
高橋 聡
日本医師会雑誌 143 (特別号); S215-S216, 2014.
22. 膀胱癌のクリニカル・パール
北村 寛
臨床泌尿器科 68; 838-842, 2014.
23. 小径腎腫瘍の自然史
舛森 直哉
臨床泌尿器科 68; 727-740, 2014.
24. 〈特集: 去勢抵抗性前立腺癌〉前立腺癌におけるがん幹細胞研究
西田 幸代、舛森 直哉
日本臨床 72; 2229-2233, 2014.

泌尿器科学講座

○主な研究内容

- 1 泌尿生殖器腫瘍学
- 2 腫瘍免疫学
- 3 前立腺肥大症の疫学的研究と臨床的研究
- 4 尿路感染症・性感染症の疫学的研究と臨床的研究
- 5 尿路粘膜における感染免疫学
- 6 尿路再生・再建医学
- 7 男子性機能の基礎的・臨床的研究
- 8 男子不妊症の成因と治療の研究
- 9 腎移植・移植免疫
- 10 性別適合手術

○Pub Med 掲載論文 (2013 年)

1. [Inoue R](#), [Hashimoto K](#), [Masumori N](#), [Takeuchi M](#), [Kitamura H](#), [Hasegawa T](#), [Tsukamoto T](#).
[Clinical and pathological features of the best candidates for active surveillance-retrospective analysis of patients with radical prostatectomy].[Article in Japanese] ([Hinyokika Kiyo](#). 2013 Sep;59(9):555-9.)
2. [Nofuji S](#), [Shindo T](#), [Mizuno T](#), [Tanaka T](#), [Kitamura H](#), [Takahashi S](#), [Masumori N](#), [Tsukamoto T](#).
[A case of IgG4-related kidney disease mimicking a renal cell carcinoma].[Article in Japanese] ([Hinyokika Kiyo](#). 2013 Aug;59(8):513-5.)
3. [Nishiyama N](#), [Kitamura H](#), [Maeda T](#), [Takahashi S](#), [Masumori N](#), [Hasegawa T](#), [Tsukamoto T](#).
Clinicopathological Analysis of Patients with Non-muscle-invasive Bladder Cancer: Prognostic Value and Clinical Reliability of the 2004 WHO Classification System. ([Jpn J Clin Oncol](#). 2013 Aug 26. [Epub ahead of print])
4. [Mizukami N](#), [Yamauchi M](#), [Koike K](#), [Watanabe A](#), [Ichihara K](#), [Masumori N](#), [Yamakage M](#).
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study. ([J Pain Symptom Manage](#). 2013 Jul 12. pii: S0885-3924(13)00309-6. doi: 10.1016/j.jpainsymman.2013.05.003. [Epub ahead of print])
5. [Ikehata Y](#), [Takahashi S](#), [Kitamura H](#), [Masumori N](#), [Tsukamoto T](#).
[A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].[Article in Japanese] ([Hinyokika Kiyo](#). 2013 Jun;59(6):369-72.)
6. [Hirobe M](#), [Masumori N](#), [Tanaka T](#), [Kitamura H](#), [Tsukamoto T](#).
Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE). ([Cancer Biol Ther](#). 2013 Jun;14(6):502-10. doi: 10.4161/cbt.24344.)
7. [Okada M](#), [Tanaka T](#), [Fukuta F](#), [Masumori N](#), [Tsukamoto T](#), [Takagi S](#), [Hasegawa T](#).
[A case of stromal tumors of uncertain malignant potential treated by radical prostatectomy].[Article in Japanese] ([Hinyokika Kiyo](#). 2013 Feb;59(2):137-40.)

8. [Sugiyama Y](#), [Masumori N](#), [Fukuta E](#), [Yoneta A](#), [Hida T](#), [Yamashita T](#), [Minatoya M](#), [Nagata Y](#), [Mori M](#), [Tsuji H](#), [Akaza H](#), [Tsukamoto T](#).
Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. ([Asian Pac J Cancer Prev](#). 2013;14(1):1-4.)
9. [Hiyama Y](#), [Takahashi S](#), [Uehara T](#), [Hashimoto J](#), [Kurimura Y](#), [Tanaka T](#), [Masumori N](#), [Tsukamoto T](#).
Significance of anaerobic bacteria in postoperative infection after radical cystectomy and urinary diversion or reconstruction. ([J Infect Chemother](#). 2013 Oct;19(5):867-70. doi: 10.1007/s10156-013-0583-z. Epub 2013 Mar 17.)
10. [Okada M](#), [Takahashi S](#), [Matsuki M](#), [Ichihara K](#), [Shima M](#), [Kitamura H](#), [Masumori N](#), [Tsukamoto T](#).
[A case of squamous cell carcinoma of the bladder in a patient with interstitial cystitis].[Article in Japanese] ([Hinyokika Kiyo](#). 2013 Jan;59(1):31-3.)
11. [Kyoda Y](#), [Kobayashi K](#), [Hirobe M](#), [Shindo T](#), [Fukuta F](#), [Hashimoto K](#), [Tanaka T](#), [Tonooka A](#), [Kitamura H](#), [Takahashi S](#), [Masumori N](#), [Hasegawa T](#), [Tsukamoto T](#).
Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. ([Int J Clin Oncol](#). 2013 Feb 13. [Epub ahead of print])
12. [Masumori N](#).
Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature. ([Patient Prefer Adherence](#). 2013;7:111-20. doi: 10.2147/PPA.S28160. Epub 2013 Jan 30.)
13. [Shindo T](#), [Masumori N](#), [Kobayashi K](#), [Fukuta F](#), [Hirobe M](#), [Tonooka A](#), [Hasegawa T](#), [Kitamura H](#), [Tsukamoto T](#).
Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable. ([BJU Int](#). 2013 May;111(6):941-5. doi: 10.1111/j.1464-410X.2012.11771.x. Epub 2013 Jan 25.)
14. [Nishida S](#), [Hirohashi Y](#), [Torigoe T](#), [Inoue R](#), [Kitamura H](#), [Tanaka T](#), [Takahashi A](#), [Asanuma H](#), [Masumori N](#), [Tsukamoto T](#), [Sato N](#).
Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. ([Cancer Sci](#). 2013 Apr;104(4):431-6. doi: 10.1111/cas.12104. Epub 2013 Feb 17.)
15. [Shimizu T](#), [Suzuki H](#), [Nojima M](#), [Kitamura H](#), [Yamamoto E](#), [Maruyama R](#), [Ashida M](#), [Hatahira T](#), [Kai M](#), [Masumori N](#), [Tokino T](#), [Imai K](#), [Tsukamoto T](#), [Toyota M](#).
Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. ([Eur Urol](#). 2013 Jun;63(6):1091-100. doi: 10.1016/j.eururo.2012.11.030. Epub 2012 Nov 23.)
16. [Kitamura H](#), [Torigoe T](#), [Hirohashi Y](#), [Asanuma H](#), [Inoue R](#), [Nishida S](#), [Tanaka T](#), [Masumori N](#), [Sato N](#), [Tsukamoto T](#).
Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. ([Virchows Arch](#). 2013

Jan;462(1):101-7. doi: 10.1007/s00428-012-1343-7. Epub 2012 Nov 20.)

17. [Fukuta F](#), [Masumori N](#), [Mori M](#), [Tsukamoto T](#).
Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study. ([Int J Urol](#). 2013 Jan;20(1):100-6. doi: 10.1111/j.1442-2042.2012.03215.x. Epub 2012 Oct 29.)
18. [Hashimoto K](#), [Masumori N](#), [Tanaka T](#), [Maeda T](#), [Kobayashi K](#), [Kitamura H](#), [Hirata K](#), [Tsukamoto T](#).
Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. ([Prostate](#). 2013 Apr;73(5):500-11. doi: 10.1002/pros.22590. Epub 2012 Sep 19.)
19. [Masumori N](#), [Tsukamoto T](#), [Horita H](#), [Sunaoshi K](#), [Tanaka Y](#), [Takeyama K](#), [Sato E](#), [Miyao N](#).
 α 1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. ([Int J Urol](#). 2013 Apr;20(4):421-8. doi: 10.1111/j.1442-2042.2012.03165.x. Epub 2012 Sep 19.)
20. [Kato S](#), [Tanaka T](#), [Kitamura H](#), [Masumori N](#), [Ito T](#), [Kawaharada N](#), [Tsukamoto T](#).
Resection of the inferior vena cava for urological malignancies: single-center experience. ([Int J Clin Oncol](#). 2013 Oct;18(5):905-9. doi: 10.1007/s10147-012-0473-x. Epub 2012 Sep 6.)
21. [Kitamura H](#), [Torigoe T](#), [Hirohashi Y](#), [Asanuma H](#), [Inoue R](#), [Nishida S](#), [Tanaka T](#), [Fukuta F](#), [Masumori N](#), [Sato N](#), [Tsukamoto T](#).
Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. ([Mod Pathol](#). 2013 Jan;26(1):117-24. doi: 10.1038/modpathol.2012.139. Epub 2012 Aug 17.)
22. [Ichihara K](#), [Kitamura H](#), [Masumori N](#), [Fukuta F](#), [Tsukamoto T](#).
Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer. ([Int J Clin Oncol](#). 2013 Feb;18(1):75-80. doi: 10.1007/s10147-011-0346-8. Epub 2011 Nov 8.)
23. [Takahashi S](#), [Hamasuna R](#), [Yasuda M](#), [Ito S](#), [Ito K](#), [Kawai S](#), [Yamaguchi T](#), [Satoh T](#), [Sunaoshi K](#), [Takeda K](#), [Suzuki N](#), [Maeda S](#), [Nishimura H](#), [Fukuda S](#), [Matsumoto T](#).
Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis. ([J Infect Chemother](#). 2013 Oct;19(5):941-5. doi: 10.1007/s10156-013-0620-y. Epub 2013 Jun 9.)
24. [Takahashi S](#).
Editorial Comment to Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: The role of procalcitonin. ([Int J Urol](#). 2013 May 12. doi: 10.1111/iju.12197. [Epub ahead of print])
25. [Takahashi S](#).
Editorial Comment to On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. ([Int J Urol](#). 2013 Feb 26. doi: 10.1111/iju.12130. [Epub ahead of print])

26. [Kunimoto Y](#), [Yasui H](#), [Touda N](#), [Okazaki M](#), [Nakata H](#), [Noda N](#), [Ikeda H](#), [Hayashi T](#), [Takahashi S](#), [Shinomura Y](#), [Ishida T](#), [Miyamoto A](#).
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy. ([J Infect Chemother](#). 2013 Aug;19(4):750-3. doi: 10.1007/s10156-012-0488-2. Epub 2012 Oct 5.)
27. [Takahashi S](#), [Hamasuna R](#), [Yasuda M](#), [Arakawa S](#), [Tanaka K](#), [Ishikawa K](#), [Kiyota H](#), [Hayami H](#), [Yamamoto S](#), [Kubo T](#), [Matsumoto T](#).
A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection. ([J Infect Chemother](#). 2013 Feb;19(1):112-7. doi: 10.1007/s10156-012-0467-7. Epub 2012 Sep 8.)
28. [Takahashi S](#), [Kurimura Y](#), [Hashimoto J](#), [Uehara T](#), [Hiyama Y](#), [Iwasawa A](#), [Nishimura M](#), [Sunaoshi K](#), [Takeda K](#), [Suzuki N](#), [Tsukamoto T](#).
Antimicrobial susceptibility and penicillin-binding protein 1 and 2 mutations in *Neisseria gonorrhoeae* isolated from male urethritis in Sapporo, Japan. ([J Infect Chemother](#). 2013 Feb;19(1):50-6. doi: 10.1007/s10156-012-0450-3. Epub 2012 Jul 14.)
29. [Kitamura H](#).
Editorial Comment to Cystectomy and urinary diversion as management of treatment-refractory benign disease: The impact of preoperative urological conditions on perioperative outcomes. ([Int J Urol](#). 2013 Sep 30. doi: 10.1111/iju.12291. [Epub ahead of print])
30. [Kitamura H](#).
Editorial Comment to Radical cystectomy and orthotopic urinary diversion in male patients with pT4a urothelial bladder carcinoma: Oncological outcomes. ([Int J Urol](#). 2013 Apr 16. doi: 10.1111/iju.12153. [Epub ahead of print])
31. [Shindo T](#), [Masumori N](#), [Kitamura H](#), [Tanaka T](#), [Fukuta F](#), [Hasegawa T](#), [Yanase M](#), [Miyake M](#), [Miyao N](#), [Takahashi A](#), [Matsukawa M](#), [Taguchi K](#), [Shigyo M](#), [Kunishima Y](#), [Tachiki H](#), [Tsukamoto T](#).
Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). ([World J Urol](#). 2013 Nov 5. [Epub ahead of print])